SCHEMBL20138356

SCHEMBL20138356

CN(C)C(=O)/N=C1\C(=O)N(C)c2ccc(Cl)cc21

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA1 P00915 3/20 0.50
CA2 P00918 3/20 0.50
CA12 O43570 1/20 0.47
KDR P35968 1/20 0.47
CA9 Q16790 1/20 0.47
CA4 P22748 1/20 0.46
CA7 P43166 1/20 0.46
PDE4D Q08499 2/20 0.41
HTR2B P41595 1/20 0.41
LMNA P02545 2/20 0.40
GAA P10253 2/20 0.40
TSPO P30536 1/20 0.40
UCHL3 P15374 1/20 0.39
UCHL1 P09936 1/20 0.39
GABRA1 P14867 3/20 0.39
GABRG2 P18507 3/20 0.39
GABRB3 P28472 3/20 0.39
GABRA5 P31644 3/20 0.39
GABRA3 P34903 3/20 0.39
GABRA2 P47869 3/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20138357 1.00 CA1 (0.50) CA1CA2CA12KDRCA9
SCHEMBL20138364 0.85 CA1 (0.49) CA1CA2CA12KDRCA9
SCHEMBL20138365 0.85 CA1 (0.49) CA1CA2CA12KDRCA9
SCHEMBL20138372 0.84 CA12 (0.52) CA1CA2CA12KDRCA9
SCHEMBL20138371 0.84 CA12 (0.52) CA1CA2CA12KDRCA9
SCHEMBL18189021 0.80 MAPT (0.57) CA1CA2CA12CA9LMNA
SCHEMBL18189020 0.80 MAPT (0.57) CA1CA2CA12CA9LMNA
SCHEMBL13113759 0.78 CA2 (0.58) CA1CA2CA12KDRCA9
SCHEMBL21999394 0.77 CA2 (0.64) CA1CA2CA12KDRCA9
SCHEMBL29174786 0.71 CA2 (0.51) CA1CA2CA12KDRCA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3288933-B1 OXINDOLE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF MUSC FOUND FOR RES DEV (US) 2021-10-06 EP disclosed
US-10370328-B2 Oxindole compounds and pharmaceutical compositions thereof MUSC FOUNDATION FOR RESEARCH DEVELOPMENT (US) 2019-08-06 US disclosed
US-20180134659-A1 OXINDOLE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF MUSC FOUNDATION FOR RESEARCH DEVELOPMENT 2018-05-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10370328-B2 Oxindole compounds and pharmaceutical compositions thereof PARK7, OPRK1, COMT CA1 4003/4885CA2 4610/4885CA12 4149/4885
US-20180134659-A1 OXINDOLE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF PARK7, OPRK1, COMT CA1 4003/4885CA2 4610/4885CA12 4149/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.